Despite significant progress and improving outcomes in the management of plasma cell
disorders, AL amyloidosis remains diagnostically and therapeutically challenging for …

A few years ago, such an editorial comment on kidney transplantation in systemic AL
amyloidosis would have been unthinkable. AL amyloidosis is a multisystem disease related …

METHODS To understand characteristics, healthcare resource utilization, costs, and clinical
outcomes associated with AL amyloidosis for patients treated in US hospitals, this …

The management of light chain (AL) amyloidosis has improved in recent years thanks to
accurate biomarker-based staging systems and response criteria and availability of novel …

The depth of hematologic response has been shown to correlate with survival and organ
responses for patients with light chain (AL) amyloidosis. We conducted a prospective trial of …

Introduction: The field of systemic amyloidosis is experiencing major advances in diagnostic
and prognostic methods coupled with a growing availability in treatment options. Areas …

The morbidity and lethality of AL amyloidosis is caused by the deposition of lg light chains as
fibrillar amyloid protein in vital organs, disrupting their function, and not by the generally low …

Amyloid light-chain amyloidosis (AL) is characterized by deposits of immunoglobulin κ or λ
free light chains (FLCs) produced by clonal bone marrow plasma cells. FLCs transform into …

Background This study characterised real-world treatment patterns, clinical outcomes, and
cost-of-illness in patients with light-chain (AL) amyloidosis. Methods Data were extracted …

We thank Dr. Solomon for his interest in our article on the management of light chain (AL)
amyloidosis [1]. At present, the treatment of AL amyloidosis is aimed at suppressing the …